Information for children, teenagers and families


Cystic fibrosis is an area of active research - both to work out to use existing treatments as effectively as possible, and to develop novel therapies. Children attending the OCCFN are currently enrolled in trials on use of regular flucloxacillin in the first 3 years (CF Start), and early use of ivacaftor in infants with the G551D gene mutation (the ARRIVAL study). For more information about these trials click the links:

Previous studies in which children from the OCCFN have taken part include TORPEDO-CF (eradication of Pseudomonas), use on inhaled mannitol in 12-17 year olds, and gene therapy trials.

Research news